 NEW YORK and SAN DIEGO, June 28, 2021 GLOBE NEWSWIRE -- Zentalis Pharmaceuticals, Inc. Nasdaq: ZNTL, a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the commencement of a proposed underwritten public offering of 150 million of shares of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Zentalis. Zentalis also expects to grant the underwriters a 30-day option to purchase up to an additional 22.5 million shares of common stock. 